Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

Exclusion Criteria

• •The subject is currently taking or has taken a medication for the treatment of Alzheimer's disease or dementia within 60 days prior to Screening Visit 1
• •The subject has a history of any significant neurologic disease other than AD.
• •In the opinion of the investigator, the subject has any clinically significant uncontrolled medical or psychiatric illness.
• •The subject has reported history of discontinuation of donepezil due to lack of efficacy.
• •The subject has a history of intolerance or adverse reaction to donepezil that led to discontinuation.
• •The subject has a known hypersensitivity to donepezil, piperidine derivatives, or any of the excipients in either donepezil hydrochloride or ABT-126 formulations.
• •Patient uses non-prescribed drugs of abuse or has a history of drug or alcohol abuse/dependence.
• •Subjects with AST and ALT values at Screening Visit 1 that are greater than or equal to 1.5-fold the upper limit of normal (ULN).